2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

By afschroeder • August 5, 2025

Bhimraj A, Falck-Ytter Y, Baden LR, Bedimo R, Cawcutt K, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Johnson S, Kim AY, Li JZ, MacBrayne C, Martin GS, Nadig N, Nakamura MM, Pearson JC, Riley L, Shafer RW, Shoham S, Shumaker AH, Tebas P, Tien PC, Loveless J, Morgan RL, Gandhi RT. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. Clin Infect Dis. 2025 Aug 4:ciaf424. doi: 10.1093/cid/ciaf424. Epub ahead of print. PMID: 40757658.

Tags: abatacept, covid-19, Harbor UCLA, Infectious Diseases, infliximab, pemivibart, Publications, vilobelimab

Metastatic Cutaneous Apocrine Carcinoma: Diagnostic and Therapeutic Challenges in a Rare Malignancy

Chan BL, Iguh C, Hwang A, Huang C. Metastatic Cutaneous Apocrine Carcinoma: Diagnostic and Therapeutic Challenges in a Rare Malignancy. Cureus. 2026 Jul 21;18(7):e113113. doi:[...]

The future of home oxygen therapy

Holland AE, Krishnan JA, Lacasse Y, Gomes H, Björklund F, Casaburi R, de Andrade J, Eakin MN, Hui D, Jacobs SS, Kawachi S, Khor YH,[...]

Emerging quantitative CCTA imaging biomarkers for cardiovascular risk stratification: a narrative review

Mora R, Irannejad K, Abbas N, Mogga P, Iskander B, Hubbard L, Roy S, Lakshmanan S, Budoff M, Krishnan S. Emerging quantitative CCTA imaging biomarkers[...]